曹 宇,邵 宇,王金收,魏世勇,史伯安*
1湖北民族學(xué)院化學(xué)與環(huán)境工程學(xué)院;2 湖北民族學(xué)院生物資源保護(hù)與利用湖北省重點(diǎn)實(shí)驗(yàn)室,恩施 445000
1,4-二氫吡啶類化合物具有抗糖尿病、神經(jīng)保護(hù)及抗血小板凝聚的生理活性,在生物和醫(yī)藥中廣泛地被用作鈣離子通道阻滯劑、抗結(jié)核劑及神經(jīng)肽YY1 受體拮抗劑[1,2]。在臨床應(yīng)用中不僅可以用于治療心絞痛、充血性心衰、高血壓、局部缺血和動(dòng)脈粥狀硬化等心腦血管疾?。?-5],還可以用于腸胃病和治療肺動(dòng)脈高壓的輔助藥物,因此,對(duì)該類化合物的研究引起了國內(nèi)外的藥物工作者的極大興趣。近年來,關(guān)于該類化合物的合成研究報(bào)道較多,主要集中于通過改變胺的結(jié)構(gòu)、醛的結(jié)構(gòu)和1,3-二羰基化合物的結(jié)構(gòu)來對(duì)其結(jié)構(gòu)進(jìn)行修飾;特別是合成方法的改進(jìn)更是諸多見于文獻(xiàn),其中尤以無溶劑一鍋法合成將產(chǎn)率提高到了90%的高度[6,7]。
松香是一種廉價(jià)的天然產(chǎn)物,在其骨架中具有多個(gè)手性中心和二萜結(jié)構(gòu),不僅具有抗癌、抗病毒和抗菌活性,還具有抗氧化、消炎、抑制胃酸分泌、鉀離子通道開發(fā)、抗驚厥、防止血吸蟲感染等生物活性,因此被廣泛用于醫(yī)藥和農(nóng)藥領(lǐng)域特別是表面活性劑等精細(xì)化學(xué)品的制備中[8-10]。本文利用松香的下游產(chǎn)品歧化松香胺,以它作為胺源與醛及1,3-二羰基化合物以無溶劑一鍋煮的方法發(fā)生Hantzsch 反應(yīng),以較高產(chǎn)率得到了松香的改性產(chǎn)品;并且實(shí)驗(yàn)中以拼合原理,首次將松香和1,4-二氫吡啶兩個(gè)活性亞結(jié)構(gòu)拼接在一起,以期得到新的先導(dǎo)化合物。這對(duì)于充分利用松香這一天然資源,開發(fā)松香資源產(chǎn)品和研究松香深度加工方法具有一定的理論意義。有關(guān)合成路線如圖1 所示。
圖1 1,4-二氫吡啶的合成路線Fig.1 Synthetic route of 1,4-dihydropyridines
歧化松香胺(工業(yè)級(jí))購自廣西梧州松脂廠,其他試劑均為國藥集團(tuán)分析純。
XL 400MHz 核磁共振儀(德國Bruker 公司);Bruker Esquire 3000 質(zhì)譜儀;PE-983 型紅外光譜儀(KBr 壓片,美國Nicolet 公司);Vario EL ⅢCHNSO元素分析儀(德國Elementar 公司);X-6 型顯微熔點(diǎn)測定儀(北京泰克儀器有限公司)。
取0.1 mol 芳香醛和0.22 mol 1,3-二羰基化合物,充分?jǐn)嚢?,然后加?.1 mol 歧化松香胺,加熱至80 ℃,攪拌回流2 h。冷卻至室溫,用大量蒸餾水沖洗3 次,固體用無水乙醇重結(jié)晶,有大量淡黃色結(jié)晶析出,抽濾,得產(chǎn)品a~n。
對(duì)目標(biāo)化合物進(jìn)行了熔點(diǎn)測定、紅外光譜、質(zhì)譜、元素分析和核磁氫譜表征。物理化學(xué)常數(shù)見表1。
表1 化合物a~n 的結(jié)構(gòu)及物理化學(xué)常數(shù)Table 1 Structure,physical constants and elemental analysis data of compounds a~n
化合物a 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.26~7.31 (2H,m,3,5-C6H5),7.21(1H,d,J=8.2 Hz,H-11),7.11~7.15 (3H,m,2,4,6-C6H5),7.02 (1H,d,J=8.2 Hz,H-12),6.87(1H,s,H-14),5.01 (1H,s,ArCH),4.05 (4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91 (3H,m,H-7,H-15),2.41 (1H,d,J=12.4,H-1),2.34 (6H,s,C=CNCH3),1.68~1.96 (6H,m,H-2,H-3,H-5,H-6),1.52~1.55 (5H,m,H-1,H-6,H-19),1.32(6H,t,OMeCH3),1.25 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:599([M +H]+);IR (KBr)ν:2987,1635,1518,1496,1382,1361 cm-1。
化合物b 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.25~7.28 (2H,m,3,5-C6H4),7.21(1H,d,J=8.2 Hz,H-11),7.11~7.15 (2H,m,2,6-C6H4),7.02 (1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),4.05 (4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91 (3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),2.28 (3H,s,PhCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32 (6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:613 ([M+H]+);IR(KBr)ν:2990,1636,1515,1493,1386,1364 cm-1。
化合物c 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.27~7.35 (4H,m,C6H4),7.21 (1H,d,J=8.2 Hz,H-11),7.02 (1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),4.05(4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91(3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32 (6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:617 ([M+H]+);IR(KBr)ν:2988,1634,1512,1493,1386,1363 cm-1。
化合物d 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.30~7.34 (4H,m,C6H4),7.21 (1H,d,J=8.2 Hz,H-11),7.02 (1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),4.05(4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91(3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32 (6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:633 ([M+H]+);IR(KBr)ν:2989,1638,1512,1497,1385,1366 cm-1。
化合物e 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.29~7.35 (4H,m,C6H4),7.21 (1H,d,J=8.2 Hz,H-11),7.02 (1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),4.05(4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91(3H,m,H-7,H-15),2.38 (1H,d,J=12.4,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32 (6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:678([M+H]+);IR(KBr)ν:2985,1633,1515,1496,1385,1365 cm-1。
化合物f 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.21 (1H,d,J=8.2 Hz,H-11),7.02(1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),6.70~6.82 (4H,m,C6H4),5.41 (1H,s,OH),5.01(1H,s,PhCH),4.05 (4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91 (3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32 (6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:615 ([M +H]+);IR(KBr)ν:2986,1638,1513,1496,1382,1365 cm-1。
化合物g 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.21 (1H,d,J=8.2 Hz,H-11),7.02(1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),6.79~6.82 (3H,m,C6H3),5.47 (1H,s,OH),5.01(1H,s,PhCH),4.05 (4H,q,OCH2),3.96 (2H,s,H-18),3.82 (3H,s,PhOCH3),2.72~2.91 (3H,m,H-7,H-15),2.38 (1H,d,J=12.4,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.26(3H,m,H-20),1.32 (6H,t,OMeCH3),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:645([M +H]+);IR(KBr)ν:2984,1632,1514,1493,1384,1365 cm-1。
化合物h 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.21 (1H,d,J=8.2 Hz,H-11),7.02(1H,d,J=8.2 Hz,H-12),6.71~6.80 (4H,m,C6H4),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),4.05 (4H,q,OCH2),3.96 (2H,s,H-18),3.82(3H,s,PhOCH3),2.72~2.91 (3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32 (6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:629 ([M +H]+);IR(KBr)ν:2982,1639,1513,1496,1384,1365 cm-1。
化合物i 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.21 (1H,d,J=8.2 Hz,H-11),7.12~7.17 (3H,m,C6H3),7.02 (1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),4.05(4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91(3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32 (6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:668 ([M+H]+);IR (KBr)ν:2985,1635,1514,1493,1384,1365 cm-1。
化合物j 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.71~7.79 (2H,m,3,5-C6H4),7.42~7.53 (2H,m,2,6-C6H4),7.21 (1H,d,J=8.2 Hz,H-11),7.02 (1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),4.05 (4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91 (3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32(6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (d,6H,J=7.0 Hz,H-16,H-17);ESI-MS m/z:644 ([M+H]+);IR(KBr)ν:2983,1636,1519,1496,1387,1365 cm-1。
化合物k 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.26 (1H,s,5-Fural-H),7.21 (1H,d,J=8.2 Hz,H-11),7.02 (1H,d,J=8.2 Hz,H-12),6.87(1H,s,H-14),6.24 (1H,m,4-Fural-H),6.05 (1H,d,J=3.6 Hz,3-Fural-H),5.01 (1H,s,PhCH),4.05(4H,q,OCH2),3.96 (2H,s,H-18),2.72~2.91(3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.32 (6H,t,OMeCH3),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:589 ([M+H]+);IR (KBr)ν:2986,1634,1518,1496,1381,1365 cm-1。
化合物l 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.26~7.31 (2H,m,3,5-C6H5),7.21(1H,d,J=8.2 Hz,H-11),7.11~7.15 (3H,m,2,4,6-C6H5),7.02 (1H,d,J=8.2 Hz,H-12),6.87(1H,s,H-14),5.01 (1H,s,PhCH),4.23 (6H,s,OCH3),3.96 (2H,s,H-18),2.72~2.91 (3H,m,H-7,H-15),2.38 (1H,d,J=12.4,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.26(3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:483 ([M+H]+);IR (KBr)ν:2985,1634,1516,1492,1381,1365 cm-1。
化合物m 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.30~7.34 (2H,m,3,5-C6H4),7.21(1H,d,J=8.2 Hz,H-11),7.04~7.10 (2H,m,2,6-C6H4),7.02 (1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),3.96 (2H,s,H-18),5.01 (1H,s,PhCH),4.23 (6H,s,OCH3),3.96(2H,s,H-18),2.72~2.91 (3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.26 (3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESIMS m/z:517([M+H]+);IR(KBr)ν:2987,1638,1513,1498,1385,1365 cm-1。
化合物n 淡黃色固體,1H NMR (400 MHz,CDCl3)δ:7.71~7.79 (2H,m,3,5-C6H4),7.42~7.53 (2H,m,2,6-C6H4),7.21 (1H,d,J=8.2 Hz,H-11),7.02 (1H,d,J=8.2 Hz,H-12),6.87 (1H,s,H-14),5.01 (1H,s,PhCH),4.23 (6H,s,OCH3),3.96 (2H,s,H-18),2.72~2.91 (3H,m,H-7,H-15),2.38 (1H,d,J=12.4 Hz,H-1),2.34 (6H,s,C=CNCH3),1.68~1.95 (6H,m,H-6,H-2,H-3,H-5),1.51~1.55 (5H,m,H-1,H-6,H-19),1.26(3H,m,H-20),1.20 (6H,d,J=7.0 Hz,H-16,H-17);ESI-MS m/z:528 ([M+H]+);IR (KBr)ν:2983,1636,1519,1496,1387,1365 cm-1。
目標(biāo)化合物的IR 中出現(xiàn)苯環(huán)和歧化松香的特征伸縮震動(dòng)吸收峰;1H NMR 中各氫的化學(xué)位移都有清晰的歸屬;質(zhì)譜數(shù)據(jù)中分子離子峰和對(duì)應(yīng)化合物的分子量相符;元素分析數(shù)值與計(jì)算值吻合良好。
無溶劑條件下,以歧化松香胺、芳香醛和1,3-二羰基化合物為原料,一鍋法合成了N-歧化松香基-1,4-二氫吡啶化合物。其中選乙酰乙酸乙酯為1,3-二羰基化合物合成時(shí)產(chǎn)率達(dá)到68%~85%。對(duì)合成的目標(biāo)化合物均進(jìn)行了元素分析、質(zhì)譜、紅外和核磁共振氫譜表征。
1 Chen GH (陳國華),Wang L (王麗),Yao XM (姚秀梅).Synthesis and biological activity of dihydropyridine calcium antagonists.Chin J Org Chem(有機(jī)化學(xué)),2010,30:997-1004.
2 Deng L (鄧蘭),Xu MX (徐鳴夏).Study on synthesis and Ca2+antagonizing activity of piperazine substituted new dihydropyridine derivatives.Chin J Pharm(中國醫(yī)藥工業(yè)雜志),2002,33:472-474.
3 Zeng RJ (曾榮今),Yao F (姚飛),Wang H (王慧),et al.Synthesis of novel 1,4-dihydropyridine tailed porphyrin compounds and investigation of their antibacterial activity.Chin J Org Chem (有機(jī)化學(xué)),2012,32:1270-1277.
4 Du JY (杜江燕),Wang BX (王炳詳),Xu F (徐飛),et al.Voltammetric and circular dichroism studies on interaction between 1,4-dihydropyridine derivatives and DNA.Chem J Chin Univ(高等學(xué)?;瘜W(xué)學(xué)報(bào)),2005,26:663-666.
5 Wu XY (伍小云),Hu AX (胡艾希),Xie YL (謝艷麗).Synthesis and characterization of 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates.Chin J Org Chem (有機(jī)化學(xué)),2006,26:93-98.
6 Cai XH(蔡小華),Zhang GL(張國林).One-pot synthesis of dihydropyridines under solvent-free condition.Chin J Org Chem (有機(jī)化學(xué)),2006,26:93-98.
7 Liu DM (柳冬梅),Du LT (杜麗婷),Sun J (孫晶),et al.Efficient synthesis of alkylenedioxy-bridged bisdihydropyridines.Chin J Org Chem (有機(jī)化學(xué)),2008,28:930-933.
8 Tong BH (童碧海),Li FY (李芳耀),Pan YM (潘英明).Study progress of dehydroabietic acid modifications.Technol Dev Chem Ind (化工技術(shù)與開發(fā)),2004,33(6):20-27.
9 Mo QJ(莫啟進(jìn)),Duan WG (段文貴),Ma XL (馬獻(xiàn)力),et al.Syntheses and fungicidal activities of 2-sustituted acylamino-5-dehydroabietyl-1,3,4-thiadiazole derivatives.Chemistry (化學(xué)通報(bào)),2012,75:160-165.
10 Chen Y(陳泳),Lin ZX(林中祥).Bioactivity of resin acids and their derivatives.Nat Prod Res Dev (天然產(chǎn)物研究與開發(fā)),2009,21:712-718.